Nurix Therapeutics (NRIX) Receivables (2020 - 2025)

Nurix Therapeutics (NRIX) has reported Receivables for 6 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables changed 0.0% year-over-year to $6.5 million; the TTM figure through Nov 2025 stood at $6.5 million (changed 0.0% YoY), while the FY2025 annual figure was $6.5 million, changed 0.0% from the prior year.
• Receivables eased to $6.5 million in Q4 2025 per NRIX's latest filing, from $20.7 million in the prior quarter.
• Across five years, Receivables topped out at $20.7 million in Q2 2025 and bottomed at $2.1 million in Q4 2022.
• Historically, Receivables has averaged $6.2 million across 5 years, with a median of $6.2 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables sank 69.57% — and 2025, when it soared 225.0%.
• Nurix Therapeutics' Receivables stood at $6.9 million in 2021, then tumbled by 69.57% to $2.1 million in 2022, then soared by 128.57% to $4.8 million in 2023, then surged by 35.42% to $6.5 million in 2024, then changed by 0.0% to $6.5 million in 2025.
• Business Quant data shows NRIX's Receivables at $6.5 million in Q4 2025, $20.7 million in Q2 2025, and $9.1 million in Q1 2025.